Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Search results